<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6032">
  <stage>Registered</stage>
  <submitdate>31/03/2016</submitdate>
  <approvaldate>31/03/2016</approvaldate>
  <nctid>NCT02730208</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation</studytitle>
    <scientifictitle>A Phase 2, Randomized, Placebo-Controlled, Double-blind Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>VX15-661-112</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - VX-661
Treatment: drugs - ivacaftor
Treatment: drugs - Placebo

Experimental: VX-661/ivacaftor - Fixed-dose combination tablet of VX-661 100-mg/ivacaftor 150-mg and an evening dose of ivacaftor 150-mg to be taken approximately 12 hours after the morning dose

Experimental: Placebo - visually-matched tablets to be taken on the same schedule as the active treatment.


Treatment: drugs: VX-661


Treatment: drugs: ivacaftor


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in CT imaging score from baseline at Week 72</outcome>
      <timepoint>from baseline at Week 72</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability assessments including number of subjects with adverse events (AEs) and serious adverse events (SAEs)</outcome>
      <timepoint>Through week 72</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Homozygous for the F508del CFTR mutation

          -  Confirmed diagnosis of CF

          -  Percent predicted forced expiratory volume (ppFEV1) =70% of predicted normal for age,
             sex, and height during screening.

          -  Stable CF disease as judged by the investigator</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to the
             subject.

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 28 days before Day 1
             (first dose of study drug)

          -  Pregnant or nursing females.

          -  Sexually active subjects of reproductive potential who are not willing to follow the
             contraception requirements.

          -  Any contraindication to undergoing chest imaging, as per the site's institutional
             guidelines</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Chermside</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Nedlands</hospital>
    <hospital> - New Lambton Heights</hospital>
    <hospital> - Parkville SIC</hospital>
    <hospital> - Randwick</hospital>
    <hospital> - South Brisbane</hospital>
    <hospital> - Subiaco</hospital>
    <hospital> - Westmead</hospital>
    <postcode> - Chermside</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Nedlands</postcode>
    <postcode> - New Lambton Heights</postcode>
    <postcode> - Parkville SIC</postcode>
    <postcode> - Randwick</postcode>
    <postcode> - South Brisbane</postcode>
    <postcode> - Subiaco</postcode>
    <postcode> - Westmead</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vertex Pharmaceuticals Incorporated</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of study is to evaluate the treatment effect of VX-661 in combination
      with ivacaftor (VX-661/ivacaftor) on chest imaging endpoints using low-dose computed
      tomography (LDCT) at Week 72, and to evaluate the safety of VX-661/ivacaftor through Week 72</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02730208</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>